Fig 1: CEACAM5 was predicted as a miR-498 target. (A) Eight common miRNAs (miR-223-3p, miR-552-3p, miR-498, miR-335-5p, miR-148a-3p, miR-361-5p, miR-148b-3p, and miR-152-3p) were overlapping in the two miRNA prediction tools (TargetScan and starBase). (B) Enrichment of CEACAM5 by eight common miRNAs (miR-223-3p, miR-552-3p, miR-498, miR-335-5p, miR-148b-3p, miR-148a-3p, miR-361-5p, and miR-152-3p) were detected by pull-down assay. ??p < 0.001 vs. Bio-NC. (C) The potential binding sequence between miR-498 and CEACAM5 was predicted in starBase (http://starbase.sysu.edu.cn/index.php). (D) The relationship between miR-498 and CEACAM5 was determined by luciferase reporter assay. ??p < 0.001 vs. miR-NC. (E) Relative miR-498 levels in 40 sets of GC tissues and adjacent normal tissues were detected via RT-PCR. (F) The relative miR-498 expressions among the GC cells (HGC-27 and AGS) and normal gastric cell (GES-1) were detected via RT-PCR. ??p < 0.001 vs. GES-1. (G) Spearman correlation coefficient was applied to test the association between the expressions of miR-498 and CEACAM5 in GC.
Fig 2: The Schematic diagram depicting the molecular interactions between anti-CEA and the tetrazine polymers.
Fig 3: Supermeres are enriched in shed membrane proteins.a, Heatmap of normalized spectral counts of APP and other select membrane proteins involved in Alzheimer’s disease. b, Immunoblot analysis of APP in the whole-cell lysate, sEV-P as well as exomeres and supermeres of DiFi cells using N-terminal (left) and C-terminal (right) APP antibodies. c, C-terminal APP fragment; i, immature APP; m, mature APP; and s, soluble APP. c, FAVS analysis of APP in the sEV-P (left), exomeres (middle) and supermeres (right) of DiFi cells. d, Immunoblot analysis of MET in SC cells and corresponding extracellular samples using both N-terminal (left) and C-terminal (right) MET antibodies. c, C-terminal MET fragment; p, pro-form MET; m, mature MET; s, soluble MET. e, FAVS analysis of MET in the DiFi sEV-P, exomeres and supermeres using MET antibody directly conjugated to Alexa Fluor-647. f, Immunoblot analysis of GPC1 in the whole-cell lysate, sEV-P, exomeres and supermeres derived from PANC-1 (left) and HREC (right) cells using a rabbit monoclonal antibody. g, FAVS analysis of GPC1 in the sEV-P (left), exomeres (middle) and supermeres (right) of DiFi cells. h, Immunoblot analysis of CEA in whole-cell lysates, sEV-Ps, exomeres and supermeres derived from DiFi (top left), LS174T (top right), LIM1215 (bottom right) and Calu-3 (bottom left) cells. i, Immunoblot analysis of CEA in the sEV-Ps, exomeres and supermeres isolated from control individuals (NL) and plasma from patients with CRC. c,e,g, The red boxes indicate APP-, GPC-1- or MET-positive particles, respectively. The percentages indicate the percent of particles that contain APP, GPC-1 or MET, respectively, above the detection limit. b,d,f,h,i, Equal quantities (30 µg) of protein from each fraction were analysed. Exom, exomere; super, supermere; WCL, whole-cell lysate.Source data
Fig 4: Flowchart of the algorithm developed for the prediction of CEA concentrations.
Fig 5: Flowchart of the subroutines used for the prediction of CEA concentrations.
Supplier Page from Abcam for Anti-Carcino Embryonic Antigen CEA antibody [EPCEAR7]